A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.
Market Scope's industry reports are meticulously prepared by a dedicated team of in-house consultants/analysts with over 100 years of collective experience.
The “2022 IOL Market Report” provides an in-depth analysis of the current intraocular lens market and forecasts performance over the next five years. It includes analysis of current markets, identification of important trends, and discussion of key factors for future success.
This report describes and forecasts performance by region for 11 categories of IOLs: commodity monofocal, enhanced monofocal/intermediate-optimized monofocal, toric, PC-toric, bifocal, trifocal, extended depth of focus (EDOF), EDOF multifocal hybrid, accommodating, postoperatively adjustable, and phakic IOLs.
Coherus BioSciences announced Aug. 2 that the US FDA had approved Cimerli (ranibizumab-eqrn) as a biosimilar product interchangeable with Lucentis (ranibizumab injection). Cimerli is approved for a...
Regeneron of Tarrytown, New York, reported Aug. 3 that its Q2-2022 US revenue for Eylea was a record $1.62 billion, a 14 percent increase over $1.42 billion in Q2-2021. Regeneron’s collaboration re...
Glaukos announced Aug. 3 that it had received 510(k) clearance from the US FDA for its iStent Infinite trabecular micro-bypass system. The iStent Infinite is indicated for use in a standalone proce...
OcuTerra Therapeutics announced Aug. 2 that the first patient had been dosed in a Phase II clinical trial evaluating its OTT166 eye drop in adults with moderately severe to severe non-proliferative...
The US Senate on Aug. 7 passed legislation that empowers Medicare to negotiate prescription drug prices on some drugs starting in 2023. Senators passed the Inflation Reduction Act with a 50-50 part...
Aerie Pharmaceuticals, maker of Rhopressa and Rocklatan for glaucoma, announced Aug. 1 that it had dosed the first patient in the Phase III COMET-3 study of its AR-15512 ophthalmic solution in dry ...
EyePoint Pharmaceuticals, maker of Yutiq and Dexycu, announced Aug. 1 that it had dosed the first patient in the Phase II DAVIO 2 trial of EYP-1901 in wet age-related macular degeneration (wet AMD)...
Nanoscope Therapeutics announced July 25 that the first patient had been dosed in a Phase II trial of its of its optogenetic monotherapy in Stargardt patients. The Dallas company is advancing Multi...
On average, our surveys take only 5 to 15 minutes to complete. Survey results help you analyze practice patterns, evaluate treatment choices, and benchmark your practice.
Benchmark reports allow you to gauge your performance, track your practice metrics over time, and compare your practice to national averages.
Additional free data tools include instant survey results, weekly polls, PowerPoint charts, and more.
Learn More Register TodayA Multi-Step Approach for Accurate & Timely Data
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.
A clinical account gives you access to survey participation and results, weekly polls, benchmark reports, a searchable news archive, and more on a personalized dashboard.